| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2005 | US20050142552 Susceptibility locus for schizophrenia |
| 06/30/2005 | US20050142535 Ogligonucleotides comprising alternating segments and uses thereof |
| 06/30/2005 | US20050142531 Drug solution of drug ions and counterions; adjust pH of solution with an ion exchange material; buffer with dipeptides and tripeptides |
| 06/30/2005 | US20050142275 Non-lauric, non-trans, non-temper fat compositions |
| 06/30/2005 | US20050142236 Composition comprising an aqueous extract of red vine leaves and a diuretic |
| 06/30/2005 | US20050142235 Preventing and/or alleviating leg discomfort from chronic venous insufficiency |
| 06/30/2005 | US20050142225 Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |
| 06/30/2005 | US20050142217 Controlling cancer by reducing its growth and improving response to therapy |
| 06/30/2005 | US20050142216 Administering amoxicillin, Vitamin B12, indomethacin, S-adenosyl-L-methionine and selinium |
| 06/30/2005 | US20050142214 Naphthalimide compositions and uses thereof |
| 06/30/2005 | US20050142210 Thrombolytic agents and methods of treatment for thrombosis |
| 06/30/2005 | US20050142209 Comprising bovine bones, cuttlefish bones, red algae and an organic acid (eg acetic acid, lactic acid or citric acid); pills; health food |
| 06/30/2005 | US20050142204 Malaria; encapsulation in animal or plant oil |
| 06/30/2005 | US20050142202 Allow delivery of a therapeutic substance to a diseased region without significant loss from blood or other fuild flow; simultaneous treatment of multiple regions of a particular lumen or network of lumens |
| 06/30/2005 | US20050142200 Antimicrobial concentrates |
| 06/30/2005 | US20050142198 Tablets; reduced side effects; cancer pain; substantially less fentanyl by weight than known oral formulation |
| 06/30/2005 | US20050142197 Generally linear effervescent oral fentanyl dosage form and methods of administering |
| 06/30/2005 | US20050142196 Stable pharmaceutical compositions containing an ACE inhibitor |
| 06/30/2005 | US20050142195 Sealing excipients separate from active materials; tablets, capsules; humidity resistance |
| 06/30/2005 | US20050142194 Chondroitin sulfate (CS); chewable solid, non-compressed; comprises gum arabic and soluble starches as structuring agents |
| 06/30/2005 | US20050142193 Galantamine formulations |
| 06/30/2005 | US20050142192 Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| 06/30/2005 | US20050142191 Pharmaceutical formulations of amyloid inhibiting compounds |
| 06/30/2005 | US20050142190 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| 06/30/2005 | US20050142189 administering a hydrophilic alpha-tocopherol ester (especially d- alpha -tocopherol polyethylene glycol 1000 succinate) and paclitaxel; may contain polyethylene glycol or a oxypropylene-oxyethylene glycol nonionic block copolymer. |
| 06/30/2005 | US20050142188 Pellets having a core coated with an antifungal and a polymer |
| 06/30/2005 | US20050142187 Encapsulated amoxicillin is released from stomach to small intestine as particles |
| 06/30/2005 | US20050142185 Gelating encapsulated alendronate; bioavailability |
| 06/30/2005 | US20050142184 Emulsion formulations for hydrophilic active agents |
| 06/30/2005 | US20050142181 Includes carrier for drug (anticancer agents; anti-sense oligonucleotide against epidermal growth factor receptor) and targeted ligand (benzamide derivative, anisamide) modifying the carrier to target the encapsulated drug to a sigma receptor over-expressed cell |
| 06/30/2005 | US20050142178 Comprises doxorubicin hydrochloride for parenteral administration; formed by evaporating solvent from lipid solution comprising phospholipids, sterol and solvent, then hydrating lipid film with aqueous hydration media (ammonium sulfate and sucrose); antitumor agents |
| 06/30/2005 | US20050142177 topical or transdermal anlgesics comprising extracts from shrubs and herbs, glutamine and fat soluble ascorbyl palmitate in the form of vitamin c; antiinflammatory agents |
| 06/30/2005 | US20050142176 Comprises protecting membrane, drug reservior layer, adhesion layer, and release liner |
| 06/30/2005 | US20050142175 Transdermal delivery of hormones without the need of penetration enhancers |
| 06/30/2005 | US20050142173 Testosterone hydroalcoholic gel for transdermal use; unique pharmacokinetic steady-state profile for testosterone |
| 06/30/2005 | US20050142167 Soluble highly branched glucose polymers and their method of production |
| 06/30/2005 | US20050142165 coatings selected from retinol, retinal, retinoic acid or p-[(E)-2-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyll-2-naphthyl)propenyl]-benzoic acid, used as grafts for eye tissues; biodegradable prosthetics |
| 06/30/2005 | US20050142163 Treatment for an orthopedic condition using agents such as silk or bleomycin |
| 06/30/2005 | US20050142155 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 06/30/2005 | US20050142154 Cosmetic preparations containing creatine and/or creatinine and organic thickeners |
| 06/30/2005 | US20050142152 Polymeric materials, their preparation and use |
| 06/30/2005 | US20050142139 and a histidine buffer; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection |
| 06/30/2005 | US20050142129 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 06/30/2005 | US20050142128 Treatment for diseases of the eye inner ear and central nervous system |
| 06/30/2005 | US20050142124 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 06/30/2005 | US20050142123 Comprising droplets of Coenzyme Q-10 dispersed in a matrix of a modified polysaccharide or a gelatin; supplement for human and animal nutrition |
| 06/30/2005 | US20050142121 Preparing cells for engraftment by differentiating human embryonic stem cells into a particular tissue type, and adapting the cell population to decrease the amount of uric acid produced by the cells upon transplantation into a subject; regenerative medicine |
| 06/30/2005 | US20050142115 Papilloma pseudovirus and preparation |
| 06/30/2005 | US20050142112 Administering recombinant adenoviral vector comprising a nucleic acid encoding p53 tumor suppressor protein; gene expression; contacting cells polyprenyl-protein transferase inhibitor FPT39; breast, colorectal, pancreatic, or prostate gland cancer treatment; antitumor and antimetastasis agents |
| 06/30/2005 | US20050142104 Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| 06/30/2005 | US20050142103 Mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood by administration of an inhibitor of GTPases such as Rac1 and Rac2 alone or in combination; specifically, methods are disclosed for mobilizing hematopoietic stem cells into subject's peripheral blood; treating cancer, anemia |
| 06/30/2005 | US20050142101 Chemically modified peptides derived from the chemokine CCL14 (HCC-1) can be used; replacement of the ultimate N-terminal amino acid of CCL14[9-74] by nonanoic acid (NNY) converts it into a potent agonist; inactivation of the chemokine receptor; antiinflammatory agents |
| 06/30/2005 | US20050142100 Tumor Necrosis Factor Binding Protein (TBP) or an isoform, mutein, fused protein, function derivative, active fraction, or salt; multiple sclerosis; corticosteroid; glatiramer |
| 06/30/2005 | US20050142099 Orally administering polyethylene glycol optionally along with lactulose to reduce plasma ammonia and/or alleviate constipation |
| 06/30/2005 | US20050142097 Two different active drugs of same ionic charge conjugated with a single resin particle( cation exchange and anion exchage resin) without displacing the other, and without retarding the initial availability of either active; a barrier cellulose or methacrylic resin coating for controlled release |
| 06/30/2005 | US20050142093 Treatment of skin with an apparatus and a benefit agent |
| 06/30/2005 | US20050142088 Hair growth stimulants, percutaneous preparations and method of stimulating hair growth |
| 06/30/2005 | US20050142073 Intranasal compositions |
| 06/30/2005 | US20050142072 Drug delivery into nose; controlling concentration into blood; using opioid or non-steroil antiinflammatory dryg |
| 06/30/2005 | US20050142071 Aerosol steroid solution formulation product with enhanced chemical resistance; container equipped with dispensing valve and having a corticosteroid of budesonide, triamcinolone acetonide, and/or rofleponide dissolved; internal surfaces coated with stainless steel, anodized aluminium or inert lining |
| 06/30/2005 | US20050142069 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 06/30/2005 | US20050139814 Benzofuran and benzothiophene derivatives useful in the treatmint of hyper-proliferative disorders |
| 06/30/2005 | US20050139810 dopes used in electronic component structures, such as light emitting diodes (OLEDs), field effect transistors (FETs) or solar cells |
| 06/30/2005 | US20050139211 Introducing aerosol into a ventilator |
| 06/30/2005 | DE10392416T5 Blutstillender Verband Hemostatic dressing |
| 06/30/2005 | DE10357452A1 Kosmetische Zubereitungen mit einem Gehalt an Licochalcon A oder einem Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A, und organischen Verdicker Cosmetic preparations containing licochalcone A or an extract from Radix Glycyrrhizae inflatae containing licochalcone A, and organic thickeners |
| 06/30/2005 | DE10357277A1 Mittel zur Verbesserung der Eisenaufnahme Means for improving the absorption of iron |
| 06/30/2005 | DE10355714A1 Wirkstoffkombination aus Kreatin und/oder Kreatinin, Phenoxyethanol und gewünschtenfalls Glycerin Active ingredient combination of creatine and / or creatinine, phenoxyethanol and, if desired, glycerol |
| 06/30/2005 | DE10355223A1 Neue Makrocyclen zur Behandlung von Krebserkrankungen New macrocycles for the treatment of cancer |
| 06/30/2005 | DE10354893A1 Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen Use of deoxypeganine for the treatment of schizophrenic psychoses |
| 06/30/2005 | CA2792467A1 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 06/30/2005 | CA2582611A1 Method of treating elevated plasma homocysteine levels in esrd patients |
| 06/30/2005 | CA2557004A1 Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| 06/30/2005 | CA2556342A1 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 06/30/2005 | CA2551944A1 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| 06/30/2005 | CA2550886A1 Polymorphic forms of tegaserod base and salts thereof |
| 06/30/2005 | CA2550726A1 Methods of preparing aripiprazole crystalline forms |
| 06/30/2005 | CA2550611A1 Use of siramesine in the treatment of cancer |
| 06/30/2005 | CA2550610A1 Use of gaboxadol for treating insomnia |
| 06/30/2005 | CA2550505A1 Copper antagonist compounds |
| 06/30/2005 | CA2550280A1 Pharmaceutical compositions containing platinum complexes with secondary xanthates and therapeutic uses thereof |
| 06/30/2005 | CA2550168A1 Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-.alpha.]pyrimidin-6-one derivatives |
| 06/30/2005 | CA2550143A1 C84 fullerenes and derivatives thereof as radical scavengers |
| 06/30/2005 | CA2550119A1 Use of gallium to treat inflammatory arthritis |
| 06/30/2005 | CA2550104A1 Use of a compound having two gold (i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (i) atoms for the treatment of cancer |
| 06/30/2005 | CA2550058A1 Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic |
| 06/30/2005 | CA2550053A1 Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
| 06/30/2005 | CA2550012A1 Urea derivative, process for producing the same and use |
| 06/30/2005 | CA2550010A1 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b |
| 06/30/2005 | CA2549916A1 Transdermal delivery system of hormones without penetration enhancers |
| 06/30/2005 | CA2549878A1 Glycosylation-deficient hepatocyte growth factor |
| 06/30/2005 | CA2549869A1 Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| 06/30/2005 | CA2549728A1 3-cyano-quinoline derivatives with antiproliferative activity |
| 06/30/2005 | CA2549724A1 Use of treprostinil to treat and prevent ischemic lesions |
| 06/30/2005 | CA2549662A1 A method for the production of enriched hop extracts having combined oestrogenic and antiproliferative bioactivity |
| 06/30/2005 | CA2549660A1 Cyclopropane compounds and pharmaceutical use thereof |
| 06/30/2005 | CA2549603A1 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
| 06/30/2005 | CA2549598A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| 06/30/2005 | CA2549589A1 Prolinylarylacetamides |
| 06/30/2005 | CA2549573A1 Dna sequence, and recombinant preparation of group 4 major allergens from cereals |